Last reviewed 2026-04-20 · How we verify

Talazoparib + Avelumab (talazoparib-avelumab)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Fatigue
• Anemia
• Nausea
• Platelet count decreased
• Diarrhea
• Weight loss
• White blood cell decreased
• Lymphocyte count decreased
• Anorexia
• Cough
• Dyspnea
• Neutrophil count decreased

Key clinical trials

• TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma (PHASE2)
• Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer (PHASE2)
• Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing (PHASE3)
• TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer (PHASE1, PHASE2)
• Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma (PHASE2)
• Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) (PHASE2)
• Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors (PHASE1, PHASE2)
• Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.